Belgium: Bone Therapeutics acquires majority position in Medsenic

Euronext Brussels and Paris listed Bone Therapeutics, a cell therapy company addressing unmet medical needs in orthopedics and other diseases, has acquired a majority stake in Medsenic, a privately held, clinical stage biotech company incorporated in France and specialized in the development of optimized formulations of arsenic Trioxide (ATO) and their applications in serious inflammatory/autoimmune…

You must be a HMI Subscriber to view this content.

Subscribe Now »